Fibrosis stiffens the myocardium by altering the composition, quantity and physical organization of the extracellular matrix surrounding cardiac cells. Collagens provide structural support, but excessive or chemically modified collagen can reduce ventricular compliance and interfere with electrical conduction. In HFpEF, this stiffening is particularly important because the left ventricle must accommodate blood during diastole, the relaxation phase of the heartbeat. When the ventricular wall becomes less compliant, filling pressures rise, blood backs up into the lungs and patients develop exertional shortness of breath. Fibrotic tissue can also create electrical discontinuities that increase vulnerability to atrial and ventricular arrhythmias. Despite its clinical importance, however, fibrosis in HFpEF is not simply a smaller version of the scar formed after a heart attack.

Following myocardial infarction, large numbers of fibroblasts can become activated myofibroblasts, a specialized state associated with contractile proteins and intensive production of scar-forming matrix. These cells help seal and stabilize damaged tissue. In HFpEF, by contrast, the disease usually develops gradually in the setting of obesity, hypertension, diabetes, ageing, kidney disease and systemic inflammation. According to the review, fibrosis in this context appears to arise from the activation of profibrotic programmes across multiple fibroblast states rather than from the dramatic expansion of one classic myofibroblast population. This distinction matters because therapies designed only to eliminate or suppress conventional myofibroblasts may overlook the broader cellular network contributing to chronic myocardial remodelling.

Advances in single-cell RNA sequencing have made it possible to examine gene activity in individual cardiac cells rather than averaging signals across an entire piece of tissue. Spatial transcriptomics adds another layer by mapping those molecular states back to their precise locations within the myocardium. Together, these technologies have revealed that cardiac fibroblasts form a diverse family of cells with distinct transcriptional profiles, anatomical niches and interactions with neighbouring cells. Some populations are closely associated with blood vessels, others with cardiomyocytes or immune cells, and still others appear to specialize in matrix maintenance or inflammatory communication. In HFpEF, different fibroblast states may acquire overlapping disease-associated programmes, allowing the fibrotic response to spread through the cardiac stroma without requiring a single dominant cell type.

One of the important programmes identified in the review involves nitrosative stress. This process develops when reactive nitrogen species, including peroxynitrite, accumulate and chemically modify proteins, lipids and nucleic acids. Nitrosative stress can disrupt signalling pathways, damage cellular structures and alter the behaviour of fibroblasts. Instead of responding appropriately to mechanical or hormonal cues, affected cells may shift toward persistent matrix production and inflammatory communication. The fibroblast response is also linked to disturbed lipid handling. In a metabolically stressed heart, changes in fatty-acid uptake, storage and oxidation can expose stromal cells to toxic lipid intermediates or alter their energy balance. These metabolic abnormalities may reinforce inflammatory and profibrotic signalling, tying the cardiac extracellular matrix to the wider metabolic disturbances that characterize HFpEF.

Fibroblasts do not operate in isolation. Cardiomyocytes, endothelial cells, pericytes, immune cells and vascular smooth-muscle cells continuously exchange signals through cytokines, growth factors, extracellular vesicles and direct cell contact. Mechanical stress caused by hypertension can activate mechanosensitive pathways in fibroblasts, while endothelial dysfunction can change the supply of oxygen, nutrients and vasoactive mediators to the myocardium. Immune cells may release transforming growth factor beta and other signals that promote matrix remodelling, while fibroblasts themselves can influence immune-cell recruitment and persistence. The result is a feedback loop in which inflammation, vascular dysfunction, altered loading conditions and extracellular-matrix stiffness continually amplify one another.

The review further presents the cardiac fibroblast as an integrator of signals arriving from organs far beyond the heart. Adipose tissue can release inflammatory mediators, adipokines and altered lipid species, particularly in obesity and insulin resistance. The bone marrow supplies immune and progenitor cells that may influence myocardial inflammation and repair. Signals originating in the gut, including microbial metabolites and inflammatory products associated with barrier dysfunction, may affect cardiovascular physiology through the circulation. The liver contributes changes in lipid metabolism and circulating proteins, while the lymphatic system regulates immune-cell trafficking and interstitial fluid clearance. Neural inputs, including sympathetic activation, can modify vascular tone, metabolism and inflammatory responses. These pathways suggest that the cardiac stroma is continuously exposed to systemic cardiometabolic stress rather than being governed solely by local cardiac injury.

This interorgan perspective may help explain why HFpEF is so heterogeneous. Two patients with similar ejection fractions can have very different combinations of hypertension, visceral adiposity, renal dysfunction, pulmonary vascular disease, inflammation and atrial arrhythmia. Those differences may produce distinct fibroblast states and distinct patterns of extracellular-matrix remodelling. A therapy that works in one molecularly defined subgroup could therefore fail in another if it targets the wrong pathway or is administered after fibrosis has become structurally entrenched. The emerging challenge is to identify which fibroblast programmes are harmful, which are protective or reparative, and how those programmes change over time.

Early proof-of-concept studies in animal models provide a reason for cautious optimism. Experimental approaches that selectively interfere with fibroblast-associated targets have reduced cardiac fibrosis, improved diastolic performance and lowered susceptibility to arrhythmias in models displaying HFpEF-like features. The therapeutic possibilities include blocking disease-associated signalling pathways, correcting fibroblast metabolism, limiting pathological responses to mechanical stress, and modifying communication between fibroblasts and immune or vascular cells. However, the biological diversity of fibroblasts creates a major safety concern. Broadly suppressing these cells could impair normal matrix maintenance, wound repair or vascular support. Future treatments will likely need to target specific disease-associated states or molecular programmes while preserving essential homeostatic functions.

The authors’ synthesis points toward a new generation of antifibrotic medicine based on precision stromal biology. Rather than viewing fibrosis as an endpoint produced by a single overactive cell type, researchers are beginning to see it as a dynamic system shaped by cellular identity, tissue location, metabolism, inflammation and communication between organs. Mapping these networks in human HFpEF tissue will be essential for determining which findings from animal models translate to patients. Biomarkers capable of identifying active fibroblast programmes, combined with imaging methods that measure diffuse fibrosis and tissue stiffness, could eventually support patient selection and treatment monitoring. If these strategies succeed, fibroblast-directed therapies may do more than reduce collagen deposition: they could interrupt the molecular circuits linking systemic metabolic stress to myocardial dysfunction, offering a targeted way to treat one of heart failure’s most persistent and least understood features.

Subject of Research: Cardiac fibroblast diversity, myocardial fibrosis and interorgan drivers in heart failure with preserved ejection fraction (HFpEF)

Article Title: Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets

Article References: Kiyar, M., Pinto, A.R., O’Sullivan, J.F. et al. “Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets.” Nature Reviews Cardiology (2026). https://doi.org/10.1038/s41569-026-01335-2

Image Credits: AI Generated

DOI: 10.1038/s41569-026-01335-2

Keywords: HFpEF, cardiac fibroblasts, myocardial fibrosis, extracellular matrix, heart failure, single-cell transcriptomics, spatial transcriptomics, cardiometabolic stress, diastolic dysfunction, antifibrotic therapy

HFpEF is characterized by impaired cardiac relaxation and stiffness despite a normal ejection fraction, differentiating it from other forms of heart failure. Until now, the metabolic mechanisms driving this dysfunction remained elusive, hampering the development of effective treatments. This study meticulously explores the intersection between pyruvate metabolism and mitochondrial regulation, focusing on post-translational modifications such as acetylation—a chemical change on proteins that can dramatically alter enzyme activity and cellular processes.

Central to this research is Dlat, a critical enzyme within the pyruvate dehydrogenase complex (PDC) that catalyzes the conversion of pyruvate to acetyl-CoA, a pivotal metabolite feeding the tricarboxylic acid (TCA) cycle. The authors identified that Dlat exerts more than its conventional roles: it acts as a driver of mitochondrial protein hyperacetylation, a modification that was observed to suppress mitochondrial fatty acid oxidation. This mechanism ultimately leads to an energy-deficient state within the cardiac muscle, contributing to the HFpEF pathological phenotype.

At the molecular level, hyperacetylation affects key components of mitochondrial fatty acid oxidation machinery, including enzymes responsible for beta-oxidation. By inducing hyperacetylation, Dlat appears to inhibit the efficient breakdown of fatty acids, the heart’s primary energy substrate under normal aerobic conditions. The resulting metabolic shift favors glucose metabolism, though this substrate switching comes at an energetic cost. The team demonstrated that this metabolic inflexibility exacerbates cardiac dysfunction observed in HFpEF, highlighting hyperacetylation as a potentially reversible pathological hallmark.

Using advanced proteomics techniques, the researchers mapped the acetylation landscape within mitochondria isolated from heart tissue exhibiting the HFpEF phenotype. Comparative analyses revealed a significant upsurge in acetyl-modified proteins, many of which align with enzymes integral to energy metabolism. This high-resolution mapping enabled the identification of hyperacetylated sites directly linked to the dampening of fatty acid oxidation pathways, providing compelling evidence for the central role of Dlat in this process.

Importantly, the study also dissected the upstream regulatory signals that govern Dlat’s acetyltransferase activity. The authors propose that alterations in the acetyl-CoA pool within mitochondria influence the enzymatic activity of Dlat, creating a feedback loop that sustains mitochondrial protein hyperacetylation. This metabolic crosstalk ultimately results in the suppression of fatty acid catabolism, reinforcing metabolic remodeling in the failing heart.

Through genetic and pharmacological manipulations in animal models, the authors demonstrated that modulating Dlat expression or activity can ameliorate HFpEF symptoms. Reducing Dlat levels or inhibiting its function attenuated mitochondrial protein hyperacetylation, restored fatty acid oxidation capacity, and improved cardiac function. These findings underscore Dlat as a promising therapeutic target, suggesting that interventions aimed at correcting acetylation imbalances could reverse metabolic defects in HFpEF.

The implications of these discoveries extend beyond heart failure, offering broader insight into mitochondrial biology and post-translational regulation of metabolism in chronic disease states. The identification of Dlat’s non-canonical role in regulating mitochondrial acetylation challenges the long-held notion of its exclusive function within pyruvate metabolism. This paradigm shift paves the way for future research into how mitochondrial enzymatic networks are rewired during pathological stress.

Moreover, this study expertly integrates cutting-edge metabolomics, molecular biology, and cardiac physiology to produce a comprehensive model of energy metabolism dysregulation in HFpEF. The multi-disciplinary approach strengthens the causal link between Dlat-mediated protein hyperacetylation and impaired fatty acid oxidation, setting a high standard for subsequent investigations seeking to understand metabolic remodeling in heart disease.

Clinically, these findings are highly consequential as HFpEF accounts for nearly half of all heart failure cases and disproportionately affects the elderly and patients with metabolic comorbidities like diabetes and obesity. Current treatment options for HFpEF are limited and primarily symptomatic. By targeting the metabolic underpinnings delineated in this research, novel drugs could emerge to improve cardiac energy efficiency, thereby enhancing patient outcomes.

Furthermore, the therapeutic strategies proposed by the authors involve modifying post-translational modifications—a relatively unexplored avenue in cardiovascular medicine. Acetylation-targeting compounds, including specific deacetylase activators or small molecules inhibiting Dlat’s abnormal acetyltransferase activity, may hold significant promise. Their translation from bench to bedside will depend on further characterization of safety and efficacy in preclinical and clinical trials.

This research also invites a re-examination of mitochondrial acetylation dynamics under physiological conditions. Understanding the balance between beneficial and maladaptive acetylation is essential for precisely manipulating these processes therapeutically. The identification of Dlat as a central modulator offers a focused target for such investigations, potentially influencing metabolic disease beyond cardiology.

In summary, the study by Wang et al. fundamentally expands our knowledge of cardiac metabolic remodeling in HFpEF by elucidating how Dlat-driven mitochondrial protein hyperacetylation restricts fatty acid oxidation. This mechanism contributes to energy deficits that compromise cardiac function. By pinpointing a reversible enzymatic process, the research charts a path toward metabolically focused therapies that could revolutionize the treatment of HFpEF and related disorders.

As the field moves forward, integrating these novel mechanistic insights with clinical phenotyping and biomarker development will be critical. Detecting early signs of aberrant mitochondrial acetylation could enable timely interventions before irreversible cardiac damage occurs. Moreover, the versatility of targeting mitochondrial metabolism underscores the broader applicability of these findings across a spectrum of metabolic diseases.

This landmark study not only illuminates the complex biochemical terrain of HFpEF but also exemplifies the power of molecular cardiology to unravel previously masked disease pathways. It is a shining example of how rigorous basic science coupled with translational ambition can yield discoveries with transformative potential for patient care worldwide.

Subject of Research: Metabolic remodeling in heart failure with preserved ejection fraction (HFpEF), focusing on the role of the pyruvate metabolism enzyme Dlat in mitochondrial protein hyperacetylation and fatty acid oxidation.

Article Title: Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart.

Article References: Wang, Y., Guo, D., Zhu, J. et al. Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70703-w

Image Credits: AI Generated